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Abstract
Background: An increasing proportion of patients present for concomitant aortic valve re-
placement (AVR) and coronary artery bypass grafting (CABG) with left ventricular (LV) dys-
function. The aim of this study was to evaluate the early outcomes and late survival of patients 
with different degrees of LV function undergoing concomitant AVR and CABG.
Methods: Between June 2001 and December 2009, patients undergoing concomitant AVR-
-CABG were identifi ed from the Australian and New Zealand Society of Cardiac and Thoracic 
Surgeons Cardiac Surgery Database Program. Demographic, operative data and post-operative 
outcomes were compared between patients with normal (> 60%), moderately impaired (30–
–60%), and severely impaired (< 30%) estimated LV ejection fraction (LVEF). Independent risk 
factors for short- and long-term mortality were identifi ed using binary logistic and Cox regres-
sion, respectively. 
Results: AVR-CABG was performed in 2,563 patients with a mean follow up of 36 months 
(range 0–106). 144 (5.6%) had severely impaired LVEF, 983 (38.3%) had moderately impaired 
LVEF while the remaining 1377 (53.7%) had normal LVEF. The 30-day mortality in patients 
with severely impaired, moderately impaired and normal LVEF was 9.0%, 4.3% and 2.9%, 
respectively. This was signifi cant on univariate (p < 0.001) but not multivariate analysis 
(p = NS). Severely impaired, moderately impaired and normal LVEF patients experienced 
5-year survivals of 63.7%, 77.1% and 82.5%, respectively. Severely impaired LVEF was an 
independent multivariable predictor of late mortality (HR 1.71; 95% CI 1.22–2.40; p = 0.002).
Conclusions: Patients with severely impaired LVEF experience worse outcomes. However, 
in the era of modern surgery, this alone should not predicate exclusion, given the established 
benefi ts of surgery in this high-risk group. (Cardiol J 2013; 20, 4: 423–430)
Key words: cardiac surgery, coronary artery bypass graft, aortic valve replacement, 
ejection fraction, left ventricular dysfunction, morbidity, survival 
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Introduction
Coronary artery disease, the leading cause of 
mortality and morbidity in the industrialised world, 
has traditionally been associated with poorer outco-
mes in patients undergoing aortic valve replacement 
(AVR) [1–4] for aortic stenosis. Improvements 
in surgical technique, myocardial preservation, 
perioperative management and earlier referral 
allows concomitant coronary artery bypass graf-
ting (CABG) to be performed in selected patients 
undergoing AVR, resulting in satisfactory rates of 
operative mortality and a signifi cant improvement in 
quality of life compared to medical therapy [1, 5–7]. 
Coronary artery disease and aortic valve 
disease are two of the most signifi cant contributors 
to left ventricular (LV) dysfunction [8]. LV dysfun-
ction is associated with poorer outcomes in most 
cardiac surgical procedures; patients with impaired 
or severely impaired ejection fraction (EF) have 
inferior outcomes following isolated AVR or CABG 
procedures [2, 4, 8–12]. 
Previous work on AVR-CABG suggested LV 
dysfunction to be a predictor of poorer outcomes 
following regression analyses [3, 6, 7, 13, 14]. How-
ever, these studies did not directly correlate LV 
dysfunction with operative outcomes in AVR-CABG 
patients. Two studies assessed small cohorts of pa-
tients with LV dysfunction undergoing AVR-CABG 
and demonstrated inferior post-operative outcomes 
[2, 9]. However, the multivariate analyses perfor-
med were specifi c to isolated AVR, not concomitant 
surgery. Long-term outcomes for concomitant AVR-
-CABG surgery were not documented in detail.
Given the paucity of data in this area and the 
growing recognition of minimally invasive appro-
aches as viable alternatives, we aimed to estab-
lish the early and late outcomes in this high-risk 
population and identify pre-operative risk factors 
that may facilitate selection and peri-operative 
optimization [15, 16].
Methods
All patients undergoing isolated concomi-
tant CABG and AVR between 1 June 2001, and 
31 December 2009, at hospitals in Australia par-
ticipating in the Australian and New Zealand 
Society of Cardiac and Thoracic Surgeons Cardiac 
Surgery Database were included in this study. Pa-
tients having isolated CABG/valvular surgery or 
other concurrent cardiac surgical procedures were 
excluded from this study. A detailed description of 
data collection and validation methods has been 
previously provided. The Ethics Committee of each 
participating hospital had previously approved the 
use of de-identifi ed patient data contained within 
the database for research and waived the need for 
individual patient consent [17, 18]. 
In the current study, the preoperative charac-
teristics, early outcomes, and long-term survival of 
patients with severely impaired (< 30%) and mo-
derately impaired (30–60%) LVEF were compared 
to those with a normal (> 60%) LVEF. 
Fourteen early post-operative outcomes were 
analyzed. These were: a) 30-day mortality, defi ned 
as death within 30 days of operation; b) Permanent 
stroke, defi ned as a new central neurologic defi cit 
persisting for > 72 h; c) Transient stroke, defi ned 
as a new transient neurologic defi cit that resolves 
completely within 72 h (transient ischemic attack 
or reversible ischemic neurologic defi cit); d) Po-
stoperative acute myocardial infarction, defi ned as 
at least 2 of the following: enzyme level elevation, 
new cardiac wall motion abnormalities, or new Q 
waves on serial electrocardiograms; e) New renal 
failure, defi ned as at least 2 of the following: serum 
creatinine increased to more than 200 µmol/L, 
doubling or greater increase in creatinine vs. pre-
operative value, or new requirement for dialysis or 
hemofi ltration; f) Prolonged ventilation (> 24 h); 
g) Multi-system failure; defined as concurrent 
failure of 2 or more of the cardiac, respiratory or 
renal systems for at least 48 h; h) Red blood cell 
transfusion; i) Gastrointestinal complications; 
defi ned as post-operative occurrence of any gastro-
intestinal complication; j) Deep sternal infection 
involving muscle and bone as demonstrated by 
surgical exploration and 1 of the following: positive 
cultures or treatment with antibiotics; k) Return to 
the operating theatre for any cause; and l) Return 
to the operating theatre for bleeding. 
To assess the impact of LV dysfunction on 
30-day mortality, logistic regression was used 
to adjust for 17 preoperative patient variables, 
with 30-day mortality as the dependent variab-
le (variables in Table 3). Other early outcomes 
were compared on univariate analysis using the 
c2 test. Long-term survival was obtained from the 
Australian National Death Index, the closing date 
for which was March 18, 2010. A Kaplan-Meier 
estimate of survival was obtained and differences in 
long-term survival were assessed by the log-rank 
test. The independent impact of LV dysfunction on 
long-term survival was assessed by constructing 
a Cox proportional hazards model using EF and 
other preoperative patient characteristics as va-
riables. Continuous variables are presented as 
mean ± 1 standard deviation and compared using 
the unpaired t test and one-way analysis of variance 
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for the 3 categories of LV function. The c2 test was 
used to compare groups of categoric variables. All 
calculated values of p were 2-sided, and p < 0.05 
was considered signifi cant. Statistical analysis was 
performed using SPSS® for Windows version 17.0 
(SPSS Inc., Chicago, Illinois). 
Results
Concomitant AVR-CABG surgery was perfor-
med in 2,563 patients at 18 Australian institutions; 
of these, estimated EF was recorded in 2,504. 
One thousand three hundred and thirty seven 
(53.7%) patients had a normal EF, 983 (38.3%) 
had a moderately impaired EF and 144 (5.6%) had 
a severely impaired EF. Pre-operative and demo-
graphic characteristics of patients, stratifi ed by EF 
are provided in Table 1. There were some notable 
differences in intra-operative variables between 
the three groups (Table 2). 
Overall 30-day mortality and in-hospital mor-
tality were 3.8% and 4.2%, respectively. The unad-
justed 30-day mortality rate was 2.9% in patients 
with normal EF, 4.3% in patients with impaired 
EF and 9.0% in patients with severely impaired 
EF. This difference was signifi cant on univariate 
analysis (p = 0.001). Logistic regression (Table 3) 
showed that impaired EF and severely impaired 
EF were not predictors of 30-day mortality on 
multivariate analysis. Patients with severely im-
paired and impaired EF had a signifi cantly higher 
mean post-operative length of stay (14.69 ± 12.38 
vs. 12.32 ± 11.07 vs. 11.16 ± 10.27, p < 0.001) 
and intensive care unit stay (113.75 ± 159.67 vs. 
68.64 ± 104.30 vs. 61.11 ± 108.47 h, p < 0.001) 
compared to patients who had normal EF (Table 4). 
The mean follow-up was 36 months (range 
0–106). Long-term survival at 3 and 5 years was 
signifi cantly lower on multivariate analysis in patients 
with severely impaired EF (p = 0.02), but not in those 
with impaired EF (p = 0.247) (88.4% vs. 84.1% vs. 
69.2%, 82.5% vs. 77.1% vs. 63.7%) compared to those 
with normal EF (Fig. 1). A Cox regression model 
predicting late mortality is shown in Table 5. 
Table 1. Comparison of pre-operative characteristics between the groups.
Preoperative variables Normal LVEF 
(n = 1,377)
Impaired LVEF 
(n = 983)
Severely impaired 
LVEF (n = 144)
P
Age [years] 73.85 ± 8.04 74.47 ± 8.43 73.02 ± 9.40 0.061
Female 497 (36.1%) 266 (27.1%) 29 (20.1%) < 0.001
Chronic obstructive pulmonary disease 221 (16.0%) 200 (20.3%) 34 (23.6%) 0.006
Diabetes mellitus 406 (29.5%) 325 (33.1%) 50 (34.7%) 0.125
Hypercholesterolemia 978 (71.0%) 707 (71.9%) 99 (68.9%) 0.701
Hypertension 1108 (80.5%) 787 (80.1%) 106 (73.6%) 0.138
Cerebrovascular disease 223 (16.2%) 196(19.9%) 25 (17.4%) 0.065
Peripheral vascular disease 166 (12.1%) 192 (19.5%) 34 (23.6%) < 0.001
Renal failure 39 (2.8%) 58 (5.9%) 7 (4.9%) 0.001
Previous cardiac surgery 59 (4.3%) 77 (7.8%) 12 (8.3%) 0.001
Recent MI (< 21 days) 91 (6.6%) 132 (13.4%) 36 (25%) < 0.001
History of congestive heart failure 380 (27.6%) 421 (42.8%) 111 (77.1%) < 0.001
Triple vessel disease 450 (32.7%) 421 (42.8%) 64 (44.4%) < 0.001
Obesity 452 (32.8%) 308 (31.3%) 34 (31.3%) 0.074
NYHA classification: – – < 0.001
Class I 273 (19.8%) 156 (15.9%) 4(2.8%) –
Class II 537 (39.0%) 327 (33.3%) 30 (20.8%) –
Class III 475 (34.5%) 384 (39.1%) 68 (47.2%) –
Class IV 58 (4.2%) 100 (10.2%) 41 (28.5%) –
Status: – – – < 0.001
Elective 1116 (81.0%) 678 (69.0%) 71 (49.3%) –
Urgent/emergency/salvage 261 (19.0%) 305 (31.0%) 73 (50.7%) –
Critical preoperative state 41 (3.0%) 67 (6.8%) 35 (24.3%) < 0.001
LVEF — left ventricular ejection fraction; MI — myocardial infarction; NYHA — New York Heart Association
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Discussion
Chronic aortic valve stenosis leads to the 
development of compensatory mechanisms, which 
promote LV hypertrophy to maintain cardiac output 
[12, 13]. Over time, these mechanisms fail and the 
resulting ventricular dilatation leads to increasing 
myocardial oxygen consumption and further decli-
ne in systolic function [12, 13, 19]. Most patients 
Table 3. Comparison of early mortality outcomes between the groups.
Preoperative variables 
Early mortality
Univariate Multivariate
Odds ratio (95% CI) P Odds ratio (95% CI) P
Age 1.06 (1.03–1.09) < 0.001 1.05 (1.04–1.06) < 0.001
Left ventricular ejection fraction – – – –
Normal 1.00 – 1.00 –
Impaired 1.49 (0.96–2.31) 0.077 1.08 (0.68–1.73) 0.745
Severely impaired 3.30 (1.72–6.33) < 0.001 1.68 (0.79–3.57) 0.177
Female 1.47 (0.97–2.22) 0.070 1.38 (0.88–2.18) 0.164
Chronic obstructive pulmonary disease 1.18 (0.72–1.96) 0.511 1.03(0.61–1.74) 0.905
Diabetes mellitus 0.94 (0.60–1.46) 0.782 0.81 (0.50–1.32) 0.408
Hypercholesterolemia 0.96 (0.61–1.49) 0.838 0.97(0.60–1.58) 0.906
Hypertension 1.09 (0.65–1.84) 0.737 1.01 (0.57–1.77) 0.986
Cerebrovascular disease 2.04 (1.30–3.19) 0.002 1.69 (1.05–2.72) 0.032
Peripheral vascular disease 2.18 (1.38–3.45) 0.001 1.51 (0.91–2.50) 0.108
Renal failure 2.12 (1.00–4.49) 0.050 1.29 (0.53–3.19) 0.576
Critical preoperative state 1.45 (1.19–1.76) < 0.001 1.80 (0.83–3.92) 0.140
Triple vessel disease 1.56 (1.04–2.34) 0.033 1.47 (0.95–2.27) 0.085
Reccent MI (< 21 days) 1.23 (0.92–1.64) 0.166 0.72 (0.37–1.43) 0.348
Obesity 0.70 (0.44–1.11) 0.128 0.98 (0.59–1.62) 0.926
History of congestive heart failure 2.11 (1.40–3.17) < 0.001 1.20 (0.76–1.92) 0.436
NYHA classification III or IV 2.85 (1.83–4.44) < 0.001 2.27 (1.39–3.70) 0.001
Non-elective procedure 2.43 (1.61–3.66) < 0.001 1.74 (1.07–2.82) 0.025
MI — myocardial infarction; NYHA — New York Heart Association
Table 2. Comparison of intra-operative characteristics between the groups.
Preoperative variables Normal LVEF 
(n = 1,377)
Impaired LVEF 
(n = 983)
Severely impaired 
LVEF (n = 144)
P
Cardiopulmonary bypass time [min] 112.93 ± 36.22 119.97 ± 35.67 117.63 ± 33.79 < 0.001
Aortic cross-clamp time [min] 142.00 ± 44.53 152.62 ± 47.30 155.70 ± 47.94 < 0.001
Type of prosthesis – – – 0.816
Bioprosthesis 1121 (81.4%) 780 (79.3%) 118 (81.9%) –
Mechanical valve 215 (15.6%) 154 (15.7%) 23 (16.0%) –
Other 7 (0.5%) 9 (0.9%) 1 (0.7%) –
Number of distal anastomoses 2.11 ± 1.14 2.34 ± 1.11 2.21 ± 1.15
Internal mammary artery used 979 (71.1%) 718 (73.0%) 90 (62.5%) 0.031
Valve size 22.77 ± 2.18 23.21 ± 2.11 23.38 ± 2.13 < 0.001
LVEF — left ventricular ejection fraction
have underlying coronary vessel disease, which 
exacerbates myocardial ischemia and further ero-
des ventricular function [12, 13]. With expanding 
geriatric populations in the developed world, aortic 
valve and coronary vessel pathology are prominent 
comorbidities that require concomitant surgery. 
Given the natural history of concomitant valve 
and vessel pathology, most patients undergoing 
combined AVR-CABG have a degree of underlying 
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ventricular compromise — traditionally a harbinger 
of poorer surgical outcomes. The purpose of this 
study was to evaluate the impact of LV dysfunction 
on early and late outcomes following concomitant 
AVR-CABG in the context of multiple patient 
comorbidities, to determine if high-risk patients 
would benefi t from an arduous, potentially risky 
procedure. 
Patients with severe LV dysfunction were 
found to have worse early outcomes. Our results 
demonstrated an unadjusted 30-day mortality rate 
of 9.0% compared with 4.3% and 2.9% in patients 
with moderately impaired and normal ventricular 
function, respectively. This was significant on 
univariate but not on multi-variate analysis. The 
NYHA classifi cation, traditionally only a subjective 
assessment of the degree of LV dysfunction, age 
and cerebrovascular disease was found to be an 
independent predictor of early mortality in our stu-
dy [20]. Similarly, Chikwe et al. [2] demonstrated 
an 8% mortality rate in patients with EF < 30% 
and severe aortic stenosis with low transvalvular 
gradients who underwent AVR-CABG, compared 
to a 2% mortality rate in patients with normal EF 
with no signifi cant difference. In our study, the 
cohort with severely impaired LVEF experience 
with greater post-operative complications that in-
cluded new renal failure, pneumonia, multi-system 
failure and prolonged ventilation; which is consi-
stent with the study by Chikwe et al. [2]. It is well 
known that LV dysfunction may compound other 
co-morbidities, which may then further contribute 
to early mortality [9, 10, 12]. Modern myocardial 
protection strategies and improved perioperative 
care has stymied the adverse effects of prolonged 
ischemia during concomitant surgery with an in-
-hospital mortality of around 10% being achievable 
in experienced centers, compared with 20% a few 
decades ago [2]. Peri-operative management of LV 
dysfunction and other concurrent comorbidities is 
paramount in order to optimize surgical outcomes 
in this high-risk group.
Long-term outcomes were signifi cantly worse 
in patients with severely impaired LV function 
and LV dysfunction was a predictor of inferior 
outcomes on multi-variate analysis. Our results are 
consistent with the existing literature. Kobayashi et 
al. [7] found survival in patients undergoing com-
Table 4. Comparison of early outcomes between the groups.
Outcome  Normal LVEF Imapired LVEF Severely imapired LVEF P
Permanent stroke 28 (2.0%) 19 (1.9%) 6 (4.2%) 0.213
Transient stroke 13 (0.9%) 9 (0.9%) 0 (0%) 0.506
Post-operative MI 13 (0.9%) 8 (0.8%) 3 (2.1%) 0.345
New renal failure 104 (7.6%) 98 (10.0%) 23 (16.0%) 0.001
Deep sternal wound infection 16 (1.2%) 11 (1.1%) 2 (1.4%) 0.961
Septicemia 26 (1.9%) 16 (1.6%) 4 (2.8%) 0.619
Pneumonia 75 (5.4%) 71 (7.2%) 15 (10.4%) 0.030
Red blood cell transfusion 814 (59.1%) 581 (59.1%) 99 (68.9%) 0.077
Multi-system failure 34 (2.5%) 17 (1.7%) 8 (5.6%) 0.018
Prolonged ventilation 175 (12.7%) 162 (16.5%) 46 (31.9%) < 0.001
Gastrointestinal complications 37 (2.7%) 15 (1.5%) 6 (4.2%) 0.062
Return to theatre 127 (9.2%) 79 (8.0%) 18 (12.5%) 0.189
Return to theatre for bleeding 62 (4.5%) 35 (3.6%) 8 (5.6%) 0.373
LVEF — left ventricular ejection fraction; MI — myocardial infarction
Figure 1. Survival outcomes, stratified by left ventricular 
ejection fraction (LVEF).
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bined AVR-CABG ranged from 63% to 72%, while 
Chikwe et al. [2] demonstrated 5-year survival in 
patients with severe EF of 65%. Similarly, Halkos 
et al. [9] demonstrated that the 5-year survival of 
AVR/CABG was 62% for EF less than 40%. Given 
the high pre-operative risk and poorer long-term 
outcomes, previous studies have advocated for 
a more cautious approach towards patient selection 
in those with advanced LV failure. However, this 
must be considered in the context of the poor natural 
history of aortic stenosis with previous reports sug-
gesting that patients have a life expectancy of only 
2 years [12]. The increased operative risk must be 
balanced with the potential gain in both length and 
quality of life. Age is ultimately a signifi cant factor 
that determines suitability for operative action, with 
several studies (including ours) demonstrating the 
detrimental effects of increasing age on short- and 
long-term outcomes following cardiac surgery [21, 
22]. Patients with impaired LVEF presented with 
concurrent medical problems; several of these 
were demonstrated to predict long-term survival. 
Thus a rigorous pre-operative work-up and medical 
optimization should be performed, considering the 
person’s age, ventricular function and other comor-
bidities in order to encompass the widest cohort of 
patients who will benefi t from surgery. Future work 
looking at the effects of concomitant surgery in oc-
togenarians with severely impaired LV dysfunction 
may be useful to identify if this cohort is a relative 
contraindication to surgery.
Indications for either a concomitant approach 
or an isolated approach for the dominant pathology 
are widely debated in the context of LV dysfunction. 
It is known that the combined approach portends 
an increased operative risk; our results refl ect 
this trend [15, 23]. Proponents of the combined 
approach argue that this population would avoid 
a second major procedure, and that subsequent 
regression in LV mass and improvement in EF 
confers upon them increased life expectancy and 
quality, and decreased re-intervention rates, which 
would not have been afforded had surgery not 
been performed [13, 19, 23, 24]. Opponents argue 
that the progression of the secondary pathology is 
slow and does not necessitate immediate action. 
Subsequent surgical intervention may be perfor-
med without additional risk. In valve replacement 
surgery for incidental aortic valve pathology, for 
instance, patients are unnecessarily exposed to ad-
ditional risk factors associated with the operation, 
and subsequently require lifetime anti-coagulation 
Table 5. Comparison of late mortality outcomes between the groups.
Preoperative variables 
Late mortality
Univariate Multivariate
Odds ratio (95% CI) P Odds ratio (95% CI) P
Age 1.05 (1.04–1.07) < 0.001 1.05 (1.04–1.06) < 0.001
Left ventricular ejection fraction – – – –
Normal 1.00 – 1.00 –
Impaired 1.39 (1.13–1.70) 0.002 1.14 (0.92–1.41) 0.247
Severely impaired 2.58 (1.91–3.49) < 0.001 1.71 (1.22–2.40) 0.002
Female 1.10 (0.90–1.34) 0.361 1.14 (0.92–1.41) 0.243
Chronic obstructive pulmonary disease 1.41 (1.13–1.77) 0.002 1.38 (1.10–1.72) 0.006
Diabetes mellitus 1.12 (0.92–1.37) 0.276 1.11 (0.89–1.37) 0.364
Hypercholesterolemia 0.86 (0.70–1.05) 0.146 0.84 (0.68–1.04) 0.117
Hypertension 0.96 (0.76–1.20) 0.699 0.91 (0.72–1.16) 0.455
Cerebrovascular disease 1.59(1.28–1.99) < 0.001 1.28(1.01–1.62) 0.041
Peripheral vascular disease 1.68 (1.34–2.10) < 0.001 1.35 (1.06–1.72) 0.015
Renal failure 2.63 (1.87–3.71) < 0.001 1.76 (1.17–2.64) 0.007
Critical preoperative state 2.81 (2.13–3.71) < 0.001 1.65 (1.15–2.36) 0.006
Triple vessel disease 1.46 (1.21–1.76) < 0.001 1.29 (1.06–1.58) 0.012
Reccent MI (< 21 days) 1.89 (1.45–2.46) < 0.001 1.25 (0.91–1.72) 0.165
Obesity 0.74 (0.59–0.92) 0.006 0.89 (0.71–1.13) 0.348
History of congestive heart failure 1.80 (1.49–2.17) < 0.001 1.40 (1.13–1.73) 0.002
NYHA classification III or IV 1.37 (1.13–1.66) 0.001 0.98 (0.79–1.21) 0.823
Non-elective procedure 1.63 (1.34–1.98) < 0.001 1.17 (0.92–1.48) 0.205
MI — myocardial infarction; NYHA — New York Heart Association
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[13, 19, 23]. Several studies, however, have shown 
that progression of asymptomatic aortic stenosis 
at the time of CABG to a state which requires an 
AVR averages between 4 and 9 years depending 
on the underlying pathology [13]. The additional 
risk of AVR-CABG in patients with LVEF is only 
slight, compared to patients with compromised 
LVEF undergoing single procedures; our results 
refl ect this trend. Given the natural history of aortic 
valve and coronary vessel disease, with its delete-
rious effects on ventricular function, concomitant 
‘prophylactic’ AVR-CABG in patients with normal 
to impaired LV dysfunction for varying severities 
of aortic stenosis at the time of CABG may be per-
formed without additional risk [13]. This may avoid 
re-intervention after initial surgery to correct the 
secondary pathology, which may have progressed 
to cause impaired or severely impaired ventricular 
function; this subjects patients to a riskier opera-
tion, which could have been avoided if they had 
undergone a concomitant procedure [13, 19, 24]. 
For patients with severely impaired LVEF, we 
have shown comparable short-term outcomes and 
long term survival compared to studies analyzing 
single procedures in the context of severely impai-
red LVEF. For isolated AVR in patients with poor 
LV function, Halkos et al. [9] showed that patients 
with an EF between 25% and 40% had an in-hospital 
mortality of 14.5% and a 5-year survival of 62%. 
A systematic review by Kunadian et al. [8] demon-
strated an operative mortality of 5.4% and a 5-year 
survival of 73.4% in patients with a mean EF of 
24.7% in patients undergoing isolated CABG. These 
results are similar to ours, which suggest that AVR-
-CABG may be performed safely in this population. 
The poor prognosis of patients with LV dys-
function requiring concomitant surgery has led to 
several arguments being mooted in the literature 
supporting percutaneous intervention techniques. 
This mainly involves trans-apical or trans-femoral 
aortic valve implantation followed by percutaneous 
coronary intervention, both of which carry a signi-
fi cantly lower peri-operative risk and mortality in 
this subset of patients [15, 16]. In patients seen to 
have a signifi cant peri-operative risk with uncon-
trolled comorbidities, this may present itself as a 
viable option [25]. However, it should not be seen 
at this stage to be a panacea for patients with LV 
dysfunction requiring concomitant surgery. Studies 
continue to suggest that CABG achieves superior 
outcomes to percutaneous coronary intervention 
in patients with left main or triple vessel disease, 
especially those with diabetes [26, 27]. Moreover, 
conventional AVR is regarded as the gold standard 
in the management of severe symptomatic aortic 
stenosis although promising outcomes have been 
reported for transcatheter AVR more recently [28, 
29]. Randomized studies, despite their logistic limi-
tations are needed further investigate the effi cacy 
of hybrid transcatheter valve and percutaneous 
revascularization procedures. 
Out study is the largest multi-centre study of 
patients undergoing concomitant AVR-CABG. The 
data presented here was subjected to both local 
validation and external auditing. Hence, the level 
of accuracy of the reported pre-, intra- and post-
-operative variables, along with the operative com-
plications and mortality rates, is high. How ever, it 
was subject to the usual caveats of retrospective 
work. Firstly, selection bias and confounding from 
unknown variables is likely to be present. Our 
dataset lacks information on drug medication pre-
operatively, at discharge and during follow-up. 
Patient characteristics were heterogeneous throu-
ghout, which may have introduced various bias and 
confounders to the results. Other long-term clinical 
endpoints which included re-occurrence of angina 
or need for further re-intervention were not ava-
ilable, which would have been useful to measure. 
Conclusions
Our results demonstrate that combined CABG/
/AVR can be performed in this challenging subgroup 
of patients with results similar to isolated AVR re-
placement with severe LV dysfunction. Given the 
limitations of drawing concrete conclusions from 
retrospective work, patients should not be denied 
surgery based on their LV dysfunction alone. Rather, 
an individualized approach should be championed, 
with due consideration of all patient factors. 
Confl ict of interest: none declared
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